Trial Profile
Randomized Phase II Study of Clofarabine Alone Versus Clofarabine in Combination With Low-Dose Cytarabine in Previously Untreated Patients Greater Than or Equal To 60 Years With AML [acute myeloid leukaemia] and High-Risk MDS [myelodysplastic syndromes]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2013
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary) ; Cytarabine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 11 Aug 2009 Actual patient number changed 70 to 95 as reported by ClinicalTrials.gov.
- 01 Dec 2008 Results were published in Blood 112: 1638-1645, No. 5, 1 Sep 2008.
- 28 May 2008 Status changed from in progress to completed, as reported on clinicaltrials.gov